

**HPTN 058 - Phase III Trial of Opiate Substitution Treatment as HIV Prevention**  
**Atlas Daily Report - September 10, 2012**  
**Retention Evaluation Date: September 3, 2012**  
**Table 1 - Participants Expected and Retained, by Study Week and Site**

	Heng County, China	Nanning, China	Xinjiang, China	Chiang Mai, Thailand	Total
Number Enrolled	411	161	478	202	1252
<b>Week 26 visit</b>					
Evaluated <sup>1</sup>	411	161	478	202	1252
Retained <sup>2</sup>	362/411 (88%)	142/161 (88%)	415/478 (87%)	190/202 (94%)	1109/1252 (89%)
Late <sup>3</sup>	45/362 (12%)	25/142 (18%)	31/415 (7%)	3/190 (2%)	104/1109 (9%)
Missed visit	49/411 (12%)	19/161 (12%)	62/478 (13%)	12/202 (6%)	142/1252 (11%)
Lost to follow-up <sup>4</sup>	0/411 (0%)	0/161 (0%)	1/478 (<1%)	0/202 (0%)	1/1252 (<1%)
<b>Week 52 visit</b>					
Evaluated <sup>1</sup>	401	155	471	202	1229
Retained <sup>2</sup>	330/401 (82%)	138/155 (89%)	373/471 (79%)	183/202 (91%)	1024/1229 (83%)
Late <sup>3</sup>	39/330 (12%)	15/138 (11%)	48/373 (13%)	15/183 (8%)	117/1024 (11%)
Missed visit	70/401 (17%)	16/155 (10%)	85/471 (18%)	19/202 (9%)	190/1229 (15%)
Lost to follow-up <sup>4</sup>	1/401 (<1%)	1/155 (1%)	13/471 (3%)	0/202 (0%)	15/1229 (1%)
<b>Week 78 visit</b>					
Evaluated <sup>1</sup>	319	80	356	202	957
Retained <sup>2</sup>	261/319 (82%)	60/80 (75%)	284/356 (80%)	174/202 (86%)	779/957 (81%)
Late <sup>3</sup>	44/261 (17%)	15/60 (25%)	54/284 (19%)	18/174 (10%)	131/779 (17%)
Missed visit	56/319 (18%)	7/80 (9%)	61/356 (17%)	28/202 (14%)	152/957 (16%)
Lost to follow-up <sup>4</sup>	2/319 (1%)	13/80 (16%)	11/356 (3%)	0/202 (0%)	26/957 (3%)
<b>Week 104 visit</b>					
Evaluated <sup>1</sup>	267	38	293	202	800
Retained <sup>2</sup>	220/267 (82%)	30/38 (79%)	221/293 (75%)	173/202 (86%)	644/800 (81%)
Late <sup>3</sup>	44/220 (20%)	1/30 (3%)	16/221 (7%)	10/173 (6%)	71/644 (11%)
Missed visit	44/267 (16%)	2/38 (5%)	61/293 (21%)	29/202 (14%)	136/800 (17%)
Lost to follow-up <sup>4</sup>	3/267 (1%)	6/38 (16%)	11/293 (4%)	0/202 (0%)	20/800 (3%)

<sup>1</sup> Evaluated participants are those whose target windows are closed or those whose target windows are not closed but completed the visits.

<sup>2</sup> Deaths are included in the retention calculation.

<sup>3</sup> Late refers to participants who completed the visits after the target windows closed but within the extended windows.

<sup>4</sup> Lost to follow-up are participants who are terminated early.

**HPTN 058 - Phase III Trial of Opiate Substitution Treatment as HIV Prevention**  
**Atlas Daily Report - September 10, 2012**  
**Retention Evaluation Date: September 3, 2012**  
**Table 1 - Participants Expected and Retained, by Study Week and Site**

	Heng County, China	Nanning, China	Xinjiang, China	Chiang Mai, Thailand	Total
Week 130 visit					
Evaluated <sup>1</sup>	5	0	3	202	210
Retained <sup>2</sup>	4/5 (80%)	-	3/3 (100%)	156/202 (77%)	163/210 (78%)
Late <sup>3</sup>	0/4 (0%)	-	0/3 (0%)	17/156 (11%)	17/163 (10%)
Missed visit	1/5 (20%)	-	0/3 (0%)	45/202 (22%)	46/210 (22%)
Lost to follow-up <sup>4</sup>	0/5 (0%)	-	0/3 (0%)	1/202 (<1%)	1/210 (<1%)
Week 156 visit					
Evaluated <sup>1</sup>	0	0	1	179	180
Retained <sup>2</sup>	-	-	1/1 (100%)	125/179 (70%)	126/180 (70%)
Late <sup>3</sup>	-	-	0/1 (0%)	0/125 (0%)	0/126 (0%)
Missed visit	-	-	0/1 (0%)	15/179 (8%)	15/180 (8%)
Lost to follow-up <sup>4</sup>	-	-	0/1 (0%)	39/179 (22%)	39/180 (22%)

<sup>1</sup> Evaluated participants are those whose target windows are closed or those whose target windows are not closed but completed the visits.

<sup>2</sup> Deaths are included in the retention calculation.

<sup>3</sup> Late refers to participants who completed the visits after the target windows closed but within the extended windows.

<sup>4</sup> Lost to follow-up are participants who are terminated early.